ALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock Has Average Target Price of $4.60 According to Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $4.60.

Separately, Weiss Ratings raised shares of ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th.

ALX Oncology Price Performance

ALX Oncology stock opened at $1.37 on Thursday. ALX Oncology has a 52 week low of $0.86 and a 52 week high of $2.66. The company’s 50 day moving average price is $1.50 and its two-hundred day moving average price is $1.82. The stock has a market cap of $189.44 million, a P/E ratio of -1.21 and a beta of 0.47. The company has a quick ratio of 9.71, a current ratio of 9.71 and a debt-to-equity ratio of 0.07.

ALX Oncology (NASDAQ:ALXO) last released its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. On average, equities analysts predict that ALX Oncology will post -0.59 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ALXO. Beacon Pointe Advisors LLC purchased a new stake in shares of ALX Oncology during the second quarter valued at approximately $26,000. Callan Family Office LLC purchased a new stake in ALX Oncology during the 2nd quarter valued at $46,000. The Manufacturers Life Insurance Company bought a new stake in shares of ALX Oncology in the 2nd quarter worth $64,000. AXQ Capital LP bought a new position in shares of ALX Oncology during the second quarter valued at $84,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of ALX Oncology during the second quarter valued at $97,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc (NASDAQ: ALXO) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of cancer. The company’s research centers on the CD47-SIRPα pathway, an immune checkpoint that cancer cells can use to evade detection and destruction by the immune system.

ALX Oncology’s lead product candidate is evorpacept, also known as ALX148, an investigational protein designed to block CD47 while supporting the activity of therapeutic antibodies and other anti-cancer treatments.